KR100589995B1 - Ｎｍｄａ 수용체 리간드로서의 피리딘 유도체 - Google Patents

Ｎｍｄａ 수용체 리간드로서의 피리딘 유도체 Download PDF

Info

Publication number
KR100589995B1
KR100589995B1 KR1020047007031A KR20047007031A KR100589995B1 KR 100589995 B1 KR100589995 B1 KR 100589995B1 KR 1020047007031 A KR1020047007031 A KR 1020047007031A KR 20047007031 A KR20047007031 A KR 20047007031A KR 100589995 B1 KR100589995 B1 KR 100589995B1
Authority
KR
South Korea
Prior art keywords
formula
compound
pyridin
dihydro
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047007031A
Other languages
English (en)
Korean (ko)
Other versions
KR20050042252A (ko
Inventor
알라닌알렉산더
부에텔만베른트
헤이츠네이다르트마리-파울르
피날드엠마누엘
빌러레네
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20050042252A publication Critical patent/KR20050042252A/ko
Application granted granted Critical
Publication of KR100589995B1 publication Critical patent/KR100589995B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020047007031A 2001-11-09 2002-11-02 Ｎｍｄａ 수용체 리간드로서의 피리딘 유도체 Expired - Fee Related KR100589995B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467.8 2001-11-09
EP01126467 2001-11-09

Publications (2)

Publication Number Publication Date
KR20050042252A KR20050042252A (ko) 2005-05-06
KR100589995B1 true KR100589995B1 (ko) 2006-06-19

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047007031A Expired - Fee Related KR100589995B1 (ko) 2001-11-09 2002-11-02 Ｎｍｄａ 수용체 리간드로서의 피리딘 유도체

Country Status (16)

Country Link
US (1) US6831087B2 (enExample)
EP (1) EP1448547B1 (enExample)
JP (1) JP4188837B2 (enExample)
KR (1) KR100589995B1 (enExample)
CN (1) CN100516061C (enExample)
AR (1) AR037221A1 (enExample)
AT (1) ATE293619T1 (enExample)
AU (1) AU2002351816B8 (enExample)
BR (1) BR0213977A (enExample)
CA (1) CA2467973C (enExample)
DE (1) DE60203820T2 (enExample)
ES (1) ES2240829T3 (enExample)
MX (1) MXPA04004308A (enExample)
PL (1) PL369544A1 (enExample)
RU (1) RU2303037C2 (enExample)
WO (1) WO2003040128A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225237A2 (de) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
CN122422302A (zh) * 2023-12-14 2026-07-17 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
MXPA04004308A (es) 2004-08-11
DE60203820D1 (de) 2005-05-25
KR20050042252A (ko) 2005-05-06
EP1448547B1 (en) 2005-04-20
CA2467973A1 (en) 2003-05-15
JP4188837B2 (ja) 2008-12-03
AU2002351816B8 (en) 2008-04-03
PL369544A1 (en) 2005-05-02
RU2004117595A (ru) 2006-01-10
AR037221A1 (es) 2004-10-27
CA2467973C (en) 2009-09-01
WO2003040128A1 (en) 2003-05-15
JP2005513004A (ja) 2005-05-12
BR0213977A (pt) 2004-08-31
US6831087B2 (en) 2004-12-14
EP1448547A1 (en) 2004-08-25
CN1585762A (zh) 2005-02-23
US20030119870A1 (en) 2003-06-26
AU2002351816B2 (en) 2008-03-06
CN100516061C (zh) 2009-07-22
DE60203820T2 (de) 2006-02-23
ES2240829T3 (es) 2005-10-16
ATE293619T1 (de) 2005-05-15
RU2303037C2 (ru) 2007-07-20

Similar Documents

Publication Publication Date Title
CA2746307C (en) Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
AU2021326209A1 (en) EFGR inhibitor, preparation method therefor, and application thereof
CN109311900A (zh) 用于配体依赖性靶蛋白质降解的单官能中间体
JP4188837B2 (ja) Ｎｍｄａレセプターリガンドとしてのピリジン誘導体
AU2005300736B2 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US20080269256A1 (en) Pyridine-2-carboxyamide derivatives
AU2014241152A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
TW200306180A (en) New compounds
TW200829558A (en) Quinazolines for PDK1 inhibition
JP2014511892A (ja) ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体
TW201035055A (en) Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CN1980923A (zh) 多环吡啶作为钾离子通道调节剂
AU2017287553A1 (en) Imidazopyrazinamine phenyl derivative and use thereof
KR20220052333A (ko) 근위축성 측색 경화증 및 관련 장애의 치료를 위한 tdp-43에 결합하는 분자
TW201038554A (en) Nicotinamide derivatives, their preparation and their therapeutic application
TWI891753B (zh) 醯胺類化合物及其用途
CA2770409A1 (en) Nitrogenous-ring acylguanidine derivative
TW201629036A (zh) 喹啉及喹唑啉化合物類
KR20230058466A (ko) 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체
AU2002351816A1 (en) Pyridine Substituted Isoquinoline Derivatives
CN111542522B (zh) 可用作激酶抑制剂的被取代的吡唑并嘧啶
JP2013536806A (ja) キナーゼ阻害剤としての重水素化複素環式化合物
EP4141003A1 (en) Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof
CN113166109B (zh) 氨基吡啶类化合物及其制备方法和用途
AU2020260426B2 (en) Phenylimidazole compound

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20100531

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110609

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110609

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000